Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2017

View Archived Issues

Spring Bank announces latest results from phase II inarigivir study

Investigational mineralocorticoid receptor antagonist KBP-5074 evaluated in phase I trial

Seres Therapeutics announces collaboration to test its microbiome therapies in cancer patients

OncoArendi Therapeutics patents arginase inhibitors

Bayer discovers new vasopressin receptor antagonists

FDA approves Genentech's Gazyva in new indication

GlaxoSmithKline discloses novel EZH2 inhibitors

Shanghai De Novo Pharmatech has presented TLR8 agonists

Amgen presents novel apelin receptor agonists

Sutent now approved in U.S. as adjuvant treatment for adults at high risk of recurrent RCC

Bayer and PeptiDream establish drug discovery collaboration

Evelo Biosciences and Mayo Clinic enter monoclonal microbial collaboration

Deerfield Management and Johns Hopkins announce creation of Bluefield Innovations

NICE recommends routine funding for Ibrance and Kisqali in England

Bayer presents preclinical data on the cardiac effects of BAY-1142524 after myocardial infarction

bb-2121 receives FDA breakthrough therapy and EMA PRIME designations

NIH grant supports MRSA osteomyelitis research at University of Rochester

FDA first to approve Hemlibra for hemophilia A

Thetis Pharmaceuticals obtains NIH grant to support development of ulcerative colitis drug

Bayer reports first-in-human data for BR-6819

FDA issues alert regarding Takeda's febuxostat for gout

Alnylam Pharmaceuticals begins rolling NDA submission for patisiran

FDA approves new formulation and pediatric indication for Tekturna

PIN Pharma begins phase I study of immune-modulator in solid tumors

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...